Shares of LeMaitre Vascular Inc. (LMAT) dropped to a 52-week low of $78.64 on Tuesday, trading at $78.77—a level just 1% above the session’s intraday trough.
The medical device manufacturer’s stock has declined 16.96% over the past year, reflecting broader investor caution despite the company’s reported growth in profit and sales compared with the prior-year period.
Second-quarter adjusted earnings came in at $0.74 per share, below the $0.81 per share expected by analysts. Revenue totaled $70.4 million, also missing the $71.47 million forecast. The underperformance followed a period of expansion in both metrics year-over-year, though the company’s guidance for the full year was revised downward in response.
LeMaitre Vascular, which specializes in vascular surgery devices, has maintained a financial health score classified as "Great" by InvestingPro, which also provides 10 exclusive insights and comprehensive Pro Research Reports on the stock. The company’s PEG ratio stands at 0.71, indicating a relatively low valuation relative to earnings growth.
The stock’s decline to its annual low underscores investor scrutiny amid mixed operational performance and revised guidance, leaving the company’s near-term trajectory subject to further reassessment.
